CARDIEX LIMITED (CDX)

The suspension of trading in the securities of CardieX Limited is expected to be lifted from the commencement of trading on Monday, 26 February 2024 following its compliance with Listing Rules 12.1 and 12.2.

The company releases pro-forma consolidated statement of financial position for 31 December 2023 (reinstatement disclosure).

The company releases a reinstatement disclosure, the pro forma balance sheet.

The company releases a notification of cessation of securities.

The company releases its Top 20 and Distribution Schedule - Listed Options.

The company releases a notice of application for quotation of securities.

Non-Renounceable Pro-Rata Entitlement Offer (partially underwritten) raises $4 million (before costs). Valid applications under the Shortfall and Top-Up Facility to be honoured in full. $0.9 million (of $1 million underwriting) taken up by the Underwriter (C2 Ventures "“ jointly owned by Chairman, Niall Cairns & CEO, Craig Cooper). Total Capital Raising of $8 million ($4 million Institutional Placement and $4 million Entitlement Offer) now complete. New shares and options under the Entitlement Offer will be issued 7 February 2024. Continued progress being made and liaisons with ASX underway as to the reinstatement of trading in the Company's shares.

The company releases a notification regarding unquoted securities.

The company releases a notice of application for quotation of securities.

The company releases the results of its meeting.

The company releases a notice of proposed issue of securities.

$4 million Entitlement Offer will close at 5:00pm (AEDT) on Thursday, 1 February 2024. $4.3 million 31 December 2023 cash balance. Cash balance to increase with Institutional Placement and Entitlement Offer proceeds.

The company lodges its December Quarterly Activities Report.

The company lodges its December Quarterly Appendix 4C.

The company releases its January 2024 Webinar Presentation.

The company releases a Supplementary Prospectus for Entitlement Offer.

The company releases a notification of cessation of securities.

The Company will host an investor webinar on Thursday, 18 January 2024 at 11:00am (AEDT)/Wednesday, 17 January 2024 at 4:00pm (PDT). The webinar will be hosted by CardieX's CEO Craig Cooper, Executive Chairman Niall Cairns, and Chief Strategy Officer Catherine Liao, who will be providing an update on the Company's business activities following recent Company announcements. Registration: https://us06web.zoom.us/webinar/register/WN_vhKmLTswTE29QFtMpC9BNw.

An Extraordinary General Meeting has been called for 9:30am (AEDT) on Thursday, 1 February 2024. The meeting is to be held at 24-26 Kent Street, Millers Point NSW 2000.

Following the launch of the Company's $4 million placement and pro rata entitlement offer of up to $4 million, in each case with attaching quoted options, the Company has been able to progress discussions with ASX as to lifting the suspension in trading of the Company's shares which has been in place since 28 September 2023.

The Company has completed the despatch of the prospectus dated 19 December 2023 for its nonrenounceable pro-rata entitlement offer of 1 new fully paid ordinary share for every 2.87 existing Shares held by eligible shareholders at an issue price of $0.08 per new Share, together with 1 quoted option for every 3 new Shares subscribed for and issued, to raise up to approximately $4.0 million.

The company provides a revised timetable for the prospectus released to the ASX on 19 December 2023.

The company releases an updated notice of proposed issue of securities.

The company releases a letter regarding the entitlement offer to the ineligible shareholders.

The company releases its December Investor Presentation.

The company issues a prospectus for a non-renounceable pro-rata offer to Eligible Shareholders on the basis of 1 New Share for every 2.87 existing Shares held on the Record Date at an issue price of $0.08 per New Share, together with 1 Quoted Option for every 3 New Shares subscribed for and issued.

The company releases a notice of proposed issue of securities.

Firm commitments received to raise up to $4.0 million through a Share Placement with institutional and sophisticated investors. Share Placement to be completed in two tranches: Tranche 1 - $1.66m in gross proceeds raised before costs (settling December 2023). Tranche 2 - $2.34m in gross proceeds raised before costs (settling February 2024 following Extraordinary General Shareholder Meeting). C2 Ventures has committed $0.79 million in the Share Placement (subject to shareholder approval) as part of its previously announced $7.5 million Funding Commitment Agreement. Launch of Entitlement Offer to existing eligible shareholders on the same terms to raise up to approximately an additional $4.0 million on the same terms as the Share Placement. Prospectus and Offer Document lodged with ASIC and ASX this day to provide pathway to resumption of trading of securities and recapitalisation of Company. C2V (and Associates) to subscribe for their entitlements of up to $0.75 million in the Entitlement Offer. CardieX in a strong capital position following receipt of operational cash inflows on 7 December 2023 and with access to remaining $6.0 million under the FCA to be provided to the Company over calendar year 2024.

The company releases a notification of cessation of securities.

The company releases a notification of cessation of securities.

The Company has today received US$4.12 million (~A$6.26 million1 ), being the full settlement of all contractual payments in relation to the Clinichain clinical trial.

The company releases its Amended Constitution.

The company releases the results of its meeting.

The company releases its AGM Executive Update.

Mitchell Asset Management extends loan expiration of R&D Facility and Working Capital Facility beyond current calendar year. Progress in claim of ~$750k Research and Development Tax Incentive Grant for the 2023 year which will be used to repay MAM facility. Largest single creditor Wilson Sonsini Goodrich & Rosati rovides signed credit note and waiver to fees of over $1,000,000. Further financial accommodation by WSGR through promissory note and payment terms for majority of US listing related costs. Overall restructure represents significant balance sheet improvement in conjunction with recently announced Funding Commitment Agreement ith C2 Ventures for up to $7.5m.

Funding Commitment Agreement signed with C2 Ventures for up to $7.5 million, including C2V's participation of up to $1.5 million in the Placement and Entitlement Offer. The FCA will cornerstone a Capital Raising Package to provide the capital required to deliver significant growth and the path to profitability. Completion of the total Capital Raising Package is expected to be announced shortly and will include as follows: A Placement (with C2V participation of up to $1 million); A pro-rata Entitlement Offer to shareholders (with C2V commitment being the balance between C2V's participation in the Placement and $1.5 million); and $6 million from C2V in 2024 under the FCA. The Placement, Entitlement Offer and shares issued to C2V under the FCA will be on the same pricing and terms (subject to shareholder approval).

The company releases its 2023 Appendix 4G and Corporate Governance Statement.

The company lodges its 2023 Annual Report.

The company lodges its September Quarterly Activities Report.

The company lodges its September Quarterly Appendix 4C.

The company's Annual General Meeting has been called for 9:30am AEDT on Thursday, 30 November 2023. The meeting is to be held at 24-26 Kent Street, Millers Point NSW 2000.

The company releases its go-to-market and product development update. With the FDA clearance of the Pulse, the company has switched their primary focus away from regulatory and engineering to their go-to-market strategy with a focus on sales and market development. The short-term focus is on key traditional markets with their clinician, pharmaceutical company, and research partners. The longer strategy involves integrating their products and solutions across multiple new healthcare sectors, with a focus on industry sectors that rely on healthcare risk management.

The company lodges its Corporate & Operating Update.

The company releases its Corporate Presentation.

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding its capital raising and annual report for the year ended 30 June 2023.

The suspension of trading in the securities of CardieX Limited will be lifted immediately following the release by CDX of an announcement regarding its finalisation of a material contract in relation to its clinical trial revenue.

New Clinical Trial Services Agreement for the provision of XCEL devices and data management services by CardieX subsidiary ATCOR. First 2 purchase orders now received. Trial is currently scheduled for multiple sites around the globe. Anticipated trial duration of ~30 months will cornerstone CardieX's revenue for the coming 2-3 financial years.

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding the finalisation of a material contract in relation to its clinical trial revenue.

The securities of Cardiex Limited will be reinstated to Official Quotation as from the commencement of trading on Tuesday, 2 February 2021 following lodgement of its Appendix 4C for the quarter ended 31 December 2020.

The company lodges its Appendix 4C and Quarterly Activities Report.

The securities of the entity will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 1 February 2021, following their failure to lodge the relevant periodic report by the due date.

The suspension of trading in the securities of Cardiex Limited will be lifted immediately following the release by CDX of an announcement regarding its progress in relation to a joint development agreement with a partner organisation.

ATCOR has this week completed a significant milestone in its engineering & technology program and has derived a series of unique and heart and arterial health features from a PPG sensor based on the Company's core SphygmoCor technology. Significant technology development milestone of wearable sensor technology for clinical and consumer applications. Technology will aim to assist in effective remote diagnosis and monitoring of hypertension and cardiovascular disease. Results to be shortly presented to ATCOR wearables partner Mobvoi, Google's official partner in China for Google's Wear OS platform. ATCOR has also been requested to demonstrate results to several major consumer wearable & technology companies.

The securities of Cardiex Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding its progress in relation to a joint development agreement with a partner organisation.

The suspension of trading in the securities of CardieX Limited will be lifted immediately following the release by CDX of an announcement regarding a customer contract.

The company has determined that the GEMDC customer contract is material to inHealth but is not currently material to CardieX. The basis of this decision is by virtue of CardieX's current equity position in inHealth (7.7%), which is prior to conversion of the currently subscribed tranche 2 convertible note, that will increase CardieX's position to 41.03% prior to the tranche 3 option to increase this stake to 50.5%.

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding a customer contract.

name changed from Atcor Medical Holdings Limited